RxDoctor Payments Data

Kathryn Herricks

Nurse Practitioner · Tampa, FLNPI 1730444597

Payments from drug & device makers

$10,630in general payments, 2019–2025

Across 48 payments — averaging $221.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Geron Corporation$1K
  • Bristol Myers Squibb$590
  • Pharmaessentia USA Corporation$520
  • Astellas Pharma US Inc$331
  • Syndax Pharmaceuticals, Inc.$291
  • plus $1K from 9 others

What the payments were for

  • Consulting fees$5,88255%
  • Speaking & faculty fees$7857%
  • Travel & lodging$1,37213%
  • Food & beverage$2,59124%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,630 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$38,872
Medicare patients
117
Services billed
575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OnuregAzacitidine14$361,489
PromactaEltrombopag Olamine13$304,101
BesremiRopeginterferon Alfa-2b-Njft18$279,416
JakafiRuxolitinib Phosphate15$263,557
InqoviDecitabine/Cedazuridine13$103,323
VenclextaVenetoclax17$38,442
Cyclosporine ModifiedCyclosporine, Modified18$2,076
Acyclovir45$637
Potassium Chloride15$219
Levofloxacin15$181
Ciprofloxacin Hcl13$133
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$37
Folic Acid12$29

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Onureg$114$361,48914 claims
NovartisPromacta$14$304,10113 claims
Pharmaessentia USA CorporationBesremi$520$279,41618 claims
Incyte CorporationJakafi$274$263,55715 claims
AbbVieVenclexta$6,492$38,44217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →